1,666 Shares in Guardian Pharmacy Services, Inc. (NYSE:GRDN) Purchased by Investment Research & Advisory Group Inc.

Investment Research & Advisory Group Inc. bought a new stake in Guardian Pharmacy Services, Inc. (NYSE:GRDNFree Report) during the 4th quarter, Holdings Channel reports. The firm bought 1,666 shares of the company’s stock, valued at approximately $34,000.

Several other hedge funds have also made changes to their positions in GRDN. Franklin Resources Inc. acquired a new position in Guardian Pharmacy Services in the third quarter valued at approximately $8,575,000. Virtu Financial LLC acquired a new position in shares of Guardian Pharmacy Services in the 3rd quarter valued at $279,000. Barclays PLC purchased a new position in shares of Guardian Pharmacy Services during the 3rd quarter worth $311,000. Wellington Management Group LLP acquired a new stake in shares of Guardian Pharmacy Services during the 3rd quarter worth about $8,400,000. Finally, Point72 DIFC Ltd purchased a new stake in Guardian Pharmacy Services in the 3rd quarter valued at about $573,000.

Insider Buying and Selling

In other news, Director Steven D. Cosler bought 7,000 shares of Guardian Pharmacy Services stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average price of $21.22 per share, with a total value of $148,540.00. Following the completion of the acquisition, the director now directly owns 17,713 shares in the company, valued at $375,869.86. The trade was a 65.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Analyst Upgrades and Downgrades

GRDN has been the subject of several research analyst reports. Raymond James initiated coverage on shares of Guardian Pharmacy Services in a research note on Monday, October 21st. They set an “outperform” rating and a $21.00 target price for the company. Truist Financial increased their price objective on shares of Guardian Pharmacy Services from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, Stephens began coverage on Guardian Pharmacy Services in a research report on Tuesday, October 22nd. They issued an “overweight” rating and a $21.00 target price on the stock.

Read Our Latest Report on Guardian Pharmacy Services

Guardian Pharmacy Services Stock Performance

Shares of NYSE:GRDN opened at $21.50 on Friday. The stock’s 50-day simple moving average is $22.17. Guardian Pharmacy Services, Inc. has a 1 year low of $14.16 and a 1 year high of $25.74.

Guardian Pharmacy Services (NYSE:GRDNGet Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($2.19). The business had revenue of $314.39 million for the quarter, compared to the consensus estimate of $303.21 million. Analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Guardian Pharmacy Services Profile

(Free Report)

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

See Also

Want to see what other hedge funds are holding GRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardian Pharmacy Services, Inc. (NYSE:GRDNFree Report).

Institutional Ownership by Quarter for Guardian Pharmacy Services (NYSE:GRDN)

Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.